Submit an Article
Online ISSN: 1945-4589
Impact Journals, LLC. is the publisher of Aging: www.impactjournals.com.
Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.
Impact Journals is a member of the Society for Scholarly Publishing.
Learn about our FREE Post-Publication Promotion Services

​​​​​​Aging-US: Prognostic signature in uveal melanoma to guide clinical therapy

09-08-2021

Aging-US published a Special Collection on Eye Disease which included "Development and validation of an immune and stromal prognostic signature in uveal melanoma to guide clinical therapy" which reported that the tumor microenvironment is known to play an important role in uveal melanoma.

Reliable prognostic signatures are needed to aid high risk patients and improve prognosis. Immune and stromal scores were calculated by applying the "ESTIMATE" algorithm. The authors found that the median survival time of the low immune/stromal score group is longer than that of the high-score group.

Figure 8. Differential putative chemotherapeutic and immunotherapeutic response. (A–G) The box plots of the estimated IC50 for the most sensitive chemotherapeutic drugs. (H) Submap analysis manifested that high risk group could be more sensitive to the programmed cell death protein 1 inhibitor (Bonferroni-corrected P = 0.02). *** P < 0.001.

Dr. Liang Hu from The Wenzhou Medical University said, "Uveal melanoma (UM) is the most common type of malignant tumor of the adult eye, and 50% of patients with UM will eventually die as a result."

Tumor microenvironment (TME) plays a pivotal role in cancer progression and therapeutic responses. Prognostic biomarkers related to TME may hold great promise in identifying molecular targets and guiding patient management. Immune and stromal cells are two major types suggested as crucial for the diagnostic and prognostic assessment of tumors. Scores can be calculated using the ESTIMATE algorithm to predict the infiltration of non-tumor cells in UM patients.

Scores can be calculated using the ESTIMATE algorithm to predict the infiltration of non-tumor cells in UM patients

The Hu Research Team concluded in their Aging-US Research Output, "our study reveals a comprehensive landscape of the immune and stromal microenvironment in UM, and provides a promising prognostic signature for UM. Patients with the high risk scores could benefit more from anti-PD-1 therapy and chemotherapy. Further investigations are needed to verify the accuracy in estimating prognoses and to test its clinical utility in patient management."

Full Text - https://www.aging-us.com/article/103779/text

Correspondence to: Liang Hu email: liang_hu@live.cn

Keywords: uveal melanoma, immune, stromal, prognosis

About Aging-US:

Cancer and aging are two sides of age-related tumorigenesis.

The mission of the journal is to understand the mechanisms surrounding aging and age-related diseases, including cancer as the main cause of death in the modern aged population.

The journal aims to promote 1) treatment of age-related diseases by slowing down aging, 2) validation of anti-aging drugs by treating age-related diseases, and 3) prevention of cancer by inhibiting aging. (Cancer and COVID-19 are age-related diseases.)

Please visit our website at www.Aging-US.com and connect with us:

For media inquiries, please contact media@impactjournals.com.